Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1481.496 - 1508.773 Dr. Andrea Apolo

And we actually didn't see a difference in terms of benefit with adjuvant pembrolizumab versus observation. And I can't explain why yet. We've done a bunch of subgroup analysis to try to tease out ureter versus renal pelvis. And the truth is these numbers are so small and the confidence intervals overlap. So it's really hard to make any conclusions from the data that we have.